Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

OBJECTIVE: This phase 2a randomised, double blind, placebo controlled, parallel group study evaluated the safety and efficacy of a first-in-class drug candidate ABX464 (obefazimod, 50 mg and 100 mg per day), which upregulates the biogenesis of the mRNA inhibitor micro-RNA (miR)-124, in combination w...

Descripción completa

Detalles Bibliográficos
Autores principales: Daien, Claire, Krogulec, Marek, Gineste, Paul, Steens, Jean-Marc, Desroys du Roure, Laurence, Biguenet, Sophie, Scherrer, Didier, Santo, Julien, Ehrlich, Hartmut, Durez, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279835/
https://www.ncbi.nlm.nih.gov/pubmed/35641124
http://dx.doi.org/10.1136/annrheumdis-2022-222228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279835/
https://www.ncbi.nlm.nih.gov/pubmed/35641124
http://dx.doi.org/10.1136/annrheumdis-2022-222228

Ejemplares similares